Chikungunya virus (CHIKV) has infected millions of people in Africa, Europe and Asia 1,2 since this alphavirus reemerged from Kenya in 2004. The severity of the disease and the spread of this epidemic virus present a serious public health threat in the absence of vaccines or antiviral therapies. Here, we describe a new vaccine that protects against CHIKV infection of nonhuman primates. We show that selective expression of viral structural proteins gives rise to virus-like particles (VLPs) in vitro that resemble replication-competent alphaviruses. Immunization with these VLPs elicited neutralizing antibodies against envelope proteins from alternative CHIKV strains. Monkeys immunized with VLPs produced hightiter neutralizing antibodies that protected against viremia after high-dose challenge. We transferred these antibodies into immunodeficient mice, where they protected against subsequent lethal CHIKV challenge, indicating a humoral mechanism of protection. Immunization with alphavirus VLP vaccines represents a strategy to contain the spread of CHIKV and related pathogenic viruses in humans.
. Given the similarity of the CHIKV genomic structure to those of other alphaviruses, CHIKV is expected to encode spikes on the virion surface that are each formed by three E1-E2 heterodimers 8, 9 , where the E1 glycoproteins mediate fusion and the E2 glycoproteins interact with the host receptor 7 . Phylogenetic analysis of CHIKV has revealed three genotypes: Asian, East, Central and South African and West African. All strains are highly related, with 95.2-99.8% amino acid similarity 10 . Although the CHIKV strains vary, the individual strains are antigenically related, so it is potentially possible to design a vaccine that works against heterologous strains 11 .
We first analyzed the immunogenicity and cross-reactivity of two disparate strains, 37997 from the older West Africa lineage and LR2006 OPY-1, the more recent strain responsible for the current epidemic. To examine the specificity of viral entry into target cells and the sensitivity of these two strains to neutralizing antibodies, we developed lentiviral vector reporters pseudotyped with glycoproteins from these two CHIKV strains. Such vectors allow analysis of the mechanism and the specificity of entry, and help to quantify antibody neutralization more readily than wild-type viruses that pose considerable biohazard concerns for routine laboratory analyses. They therefore provide a useful tool for the study of CHIKV entry as well as for vaccine development [12] [13] [14] . We inserted CHIKV envelope genes encoding the native polypeptide, E3-E2-6K-E1 (Fig. 1a) , from the 37997 and LR2006 OPY-1 strains into an expression vector (E 37997 and E OPY-1 ). We verified incorporation of each set of CHIKV envelope proteins into the pseudotyped lentiviral vectors by buoyant density gradient sedimentation of the virus. We detected CHIKV envelope and HIV-1 Gag proteins in the same buoyant density fraction as lentivirus particles (Supplementary Fig. 1 ). The 37997 and LR2006 OPY-1 CHIKV-pseudotyped lentiviral vectors infected several cell lines permissive for viral replication 15 (Fig. 1b) . We then measured their ability to express a luciferase reporter in 293A human renal epithelial cells and found that entry was dose dependent (Fig. 1b) , whereas an empty control vector, devoid of CHIKV envelope proteins, did not infect these cell lines. To determine whether entry occurred through the same mechanism used by native virus, we analyzed pH and the endosome dependence of entry 13 . CHIKV infects cells through pH-dependent cell fusion 15 ; thus, addition of ammonium chloride or chloroquine, which prevent acidification of the endosome, caused a dose-dependent reduction We also detected capsid and E1 and E2 proteins in the supernatant by western blotting after transfection of the C-E 37997 or C-E OPY-1 vector, suggesting that CHIKV VLPs had been generated. We purified VLPs by in CHIKV pseudotyped vector entry (Fig. 1c) . We observed a similar inhibition of entry with a lentiviral vector pseudotyped with vesicular stomatitis virus G protein (VSV-G), which is known to mediate entry in this fashion, but not with amphotropic murine leukemia virus glycoprotein 70, which mediates entry by a pH-independent mechanism 13, 16 . These findings indicate that lentiviral vectors pseudotyped with CHIKV envelope mediate entry through the same mechanism as wild-type virus. Next, we examined a commercially available immune serum from mice infected with an established CHIKV strain. Incubation of the immune sera with the CHIKV-pseudotyped lentiviral vector, but not a VSV-Gpseudotyped vector, inhibited entry (Fig. 1d) . We could therefore quantify the specificity and potency of the neutralizing antibodies without needing to expose laboratory workers to infectious virus.
We next analyzed eukaryotic expression vectors encoding C-E3-E2-6K-E1 from strains 37997 and LR2006 OPY-1 (C-E 37997 and C-E OPY-1 ) for their ability to give rise to VLPs. We transfected 293T human kidney cells with C-E 37997 or C-E OPY-1 or E 37997 or E OPY-1 ( Fig. 2a) and confirmed expression in the cell lysates by western blotting (Fig. 2a) .
Chikungunya genome Supplementary  Fig. 1a) . and in many cases are too small to be visible. 
E1 6K
Figure 2 Characterization of CHIKV VLPs. (a) Top, schematic representation of the CHIKV C-E or E expression vectors used for DNA vaccine and VLP production. The CHIKV structural polyproteins capsid plus envelope (C-E) or E alone from strains 37997 and LR2006 OPY-1 were inserted into a CMV/R expression vector 14 . Bottom, western blotting of 293T cells transfected with the above plasmids 48 h after transfection 33 , as previously described (Supplementary Methods). (b) Left, buoyant density fractionation of VLPs purified from fractionated supernatants of 293F cells transfected with the C-E expression vector (C-E 37997 ) (top) and protein expression (bottom), as determined by western blot analysis. Right, transmission electron microscopic image of fractionated VLPs. Scale bar, 100 nm. (c) Cryoelectron microscopy reconstruction of CHIKV VLP. Left, the central cross-section through the cryoelectron microscopy maps of CHIKV VLP. The orientations of the icosahedral (two-, three-and fivefold) axes as well as the quasi-threefold (q3) axis are shown with white lines. Right, a shaded-surface representation of the three-dimensional density map of CHIKV VLP, viewed along an icosahedral twofold axis, resembling Sindbis virus 8, 9, 18 (Supplementary Fig. 2 ). The white triangle marks the boundary of an icosahedral asymmetric unit. The numbers show the positions of the icosahedral two-, three-and fivefold axes limiting an asymmetric unit. The map is calculated to 18 Å resolution. l e t t e r s strain 37997; 525 for DNA C-E 37997 against strain LR2006 OPY-1). These results suggested that the VLPs elicit a more potent neutralizing antibody response than DNA vaccines.
To characterize the VLP-induced immune responses in a model with stronger predictive value for humans, we immunized rhesus macaques with VLPs. Monkeys received intramuscular injections of VLP 37997 or PBS alone as a control. We tested sera from immunized and control monkeys against CHIKV strain 37997-and LR2006 OPY-1-pseudotyped lentiviral vectors in vitro. All nonhuman primates immunized with VLPs developed substantial neutralizing activity to both homologous and heterologous strains after primary immunization that increased after boosting ( Fig. 3c ; IC 50 titer of 10,219 against strain 37997, IC 50 titer of 15,072 against strain LR2006 OPY-1). Notably, there was slightly better neutralization of LR2006 OPY-1 compared to 37997 in both mice and monkeys, although these effects were not substantial, suggesting that the LR2006 OPY-1 virus may present a conserved epitope to the immune system better than the 37997 virus. To confirm that these antibodies neutralize CHIKV-pseudotyped lentiviral vectors similarly to wild-type infectious virus, we performed a plaque reduction neutralization test (PRNT) against the CHIKV strain LR2006 OPY-1. The antisera from the immunized monkeys mediated neutralization of LR2006 OPY-1 at a half-maximal PRNT of 40,133 (Fig. 3d) . These data suggest that measurement of neutralizing antibodies with the pseudotyped lentiviral vector assay correlates with the PRNT assay of wild-type virus and that all VLP-immunized monkeys generated potent neutralizing antibody responses against CHIKV.
To establish a CHIKV challenge model in monkeys, we injected two naive rhesus monkeys intravenously with a high-titer LR2006 OPY-1 virus stock. Viremia commenced at 6 h and lasted until at least 72 h after challenge in these monkeys, with the peak viremia at 24 h after infection (Supplementary Fig. 3a) . As in humans, infection in nonhuman primates resulted in viremia and was not lethal. In addition, we observed a similar transient acute lymphopenia and a proinflammatory response, as measured by transient neutrophilia and an increase in monocyte counts buoyant density gradient sedimentation. The yield of VLPs from strain 37997 was 10-20 mg l -1 , approximately 100 times more than that from strain LR2006 OPY-1. For this reason and because of the high degree of amino acid similarity among CHIKV strains, we used the 37997 strain to produce VLPs. Fractionation of clarified supernatant showed the greatest incorporation of E1 complexed with E2 (E1-E2) into the VLPs at a density of 1.2 g ml -1 (Fig. 2b) , comparable to the density of wild-type CHIKV 17 . Examination of the purified fraction from strain 37997 by electron microscopy revealed VLPs with the same morphologic appearance as wild-type virus (Fig. 2b) .
Cryoelectron microscopy and three-dimensional image reconstruction, assuming icosahedral symmetry, showed that the VLPs had an external diameter of 65 nm and a core diameter of 40 nm (Fig. 2c) . The potent immunogenic E1-E2 glycoproteins are organized into 240 heterodimers, assembled into 80 glycoprotein spikes arranged with triangulation number (T) = 4 quasisymmetry on the surface of the VLPs (Fig. 2c) , closely similar to the structure of Sindbis virus ( Supplementary  Fig. 2 ) 8, 9, 18 . (The number of molecular subunits that occur within the icosahedral asymmetric unit with quasisimilar environments is known as the triangulation number, T, and is a crucial determinant for virus assembly 19 .)
Because of the ease of DNA vaccine preparation and its broad applicability, we compared the relative immunogenicity of plasmid DNA to VLP vaccines in mice by immunizing with DNA vaccines encoding C-E or E (strains 37997 and LR2006 OPY-1) or VLPs from strain 37997 (VLP 37997 ) in the presence or absence of the Ribi immune stimulatory adjuvant. BALB/c mice injected twice intramuscularly with VLPs with adjuvant generated the highest-titer neutralizing responses against both the homologous strain 37997 ( Fig. 3a; half-maximal inhibitory concentration (IC 50 ) titer of 10,703) and the heterologous strain LR2006 OPY-1 ( Fig. 3b; IC 50 titer of 54,600). Although three immunizations with the plasmids encoding C-E and E from both strains elicited neutralizing responses, these titers were less than 5% of those elicited in VLPimmunized mice (Fig. 3a,b ; IC 50 titer of 319 for DNA C-E 37997 against l e t t e r s tecting against CHIKV infection by passive transfer of IgG from infected humans in this immunodeficient model 21 . Here we intravenously transferred purified total IgG from immunized or control monkeys into these Ifnar1 -/-immunodeficient mice and challenged the recipient mice intradermally with a lethal dose of LR2006 OPY-1 24 h later. Recipients of purified IgG from CHIKV-immunized monkeys showed no detectable viremia after challenge and were completely protected from lethality (Fig. 4c,d) . In contrast, all mice that received purified IgG from control monkeys showed severe infection and viremia and died (Fig. 4c,d) . These results indicate that humoral immune responses induced by CHIKV VLPs confer protection against CHIKV infection. To date, there has been limited success in developing a safe and effective CHIKV vaccine. A live attenuated CHIKV vaccine candidate 22, 23 caused transient arthralgia in volunteers 24 . Other efforts, including a formalin-killed vaccine 25, 26 , a Venezuelan equine encephalitis-CHIKV chimeric live attenuated vaccine 27 and a consensus-based DNA vaccine 28 , have not yet proven both safe and effective. The development of a safe and effective CHIKV vaccine will require additional evaluation in humans. However, the safety and efficacy of VLP vaccines in general 29 make them promising candidates for further study.
VLPs are known to be highly immunogenic and elicit higher-titer neutralizing antibody responses than subunit vaccines based on individual proteins [29] [30] [31] . Such VLPs authentically present viral spikes and other surface components in a repetitive array that effectively elicits recognition by B cells to stimulate antibody secretion 29, 30 . This recognition leads to B cell signaling and major histocompatibility complex class II upregulation that facilitates the generation of high-titer, specific antibodies. VLPs from other viruses, including hepatitis B virus and human papillomavirus, elicit high-titer neutralizing antibody responses that contribute to protective immunity in humans 31, 32 . The vaccine described here represents what is to our knowledge the first use of recombinant VLPs to prevent infection by alphaviruses. At a time when there are no commercially available vaccines and with the emergence of CHIKV transmission from insect vectors, a VLP vaccine has the potential to have a considerable impact on the spread of this disease. Changes in trade, travel and global climate have aided the spread of mosquito species worldwide, which may potentially cause other alphavirus outbreaks. Our approach may prove useful for vaccine development against other pathogenic alphaviruses, including Western, Eastern and Venezuelan equine encephalitis viruses, O'nyong-nyong virus and Ross River virus.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/nm/.
Note: Supplementary information is available on the Nature Medicine website.
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We thank K. Nagashima for help with electron microscopy and J.D. Yoder for initiating cryoelectron microscopy reconstruction. We also thank A. Tislerics and J. Stein for help with manuscript preparation, B. Hartman for graphic arts and members of the Nabel lab for helpful discussions. We thank R. Seder and D.D. Fig. 3b) . We assessed the ability of the VLP vaccine to protect against infection by intravenous challenge of monkeys immunized with VLPs or sham-immunized controls using the same high-titer LR2006 OPY-1 virus stock 15 weeks after the final immunization. In this model, all immunized monkeys controlled the challenge virus completely (Fig. 4a) . In contrast, we observed viremia in all of the control monkeys injected with CHIKV, as in the pilot experiment. Similarly, monocyte counts were markedly increased in control monkeys 4 d after challenge, whereas they remained unchanged in vaccinated monkeys ( Fig. 4b; control at day 0 versus day 7, P = 0.0015; VLPs at day 0 versus day 7, P = 0.38). These data suggest that immunization with VLPs protects against both viremia and the inflammatory consequences of infection.
To define the mechanism of protection in these monkeys, we investigated whether or not immune IgG could protect against lethal challenge in an adoptive transfer model. Previous studies have shown that immunodeficient mice with defective type 1 interferon signaling (interferon-α/β receptor-1 knockout, Ifnar1 -/-) are susceptible to lethal CHIKV infection, showing pathological manifestations of infection 20 and providing a model to evaluate immune mechanisms of protection. For example, it was previously shown that antibodies have a key role in pro- l e t t e r s
